Join

Compare · BDX vs NPCE

BDX vs NPCE

Side-by-side comparison of Becton Dickinson and Company (BDX) and Neuropace Inc. (NPCE): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both BDX and NPCE operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
  • BDX is the larger of the two at $72.89B, about 361.2x NPCE ($201.8M).
  • Over the past year, BDX is down 25.7% and NPCE is up 44.9% - NPCE leads by 70.6 points.
  • BDX has been more active in the news (9 items in the past 4 weeks vs 3 for NPCE).
  • BDX has more recent analyst coverage (25 ratings vs 15 for NPCE).
PerformanceBDX-25.68%NPCE+44.94%
2025-04-28+0.00%2026-04-24
MetricBDXNPCE
Company
Becton Dickinson and Company
Neuropace Inc.
Price
$152.11-1.77%
$16.84-0.09%
Market cap
$72.89B
$201.8M
1M return
-3.89%
+25.26%
1Y return
-25.68%
+44.94%
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Exchange
NYSE
NASDAQ
IPO
2021
News (4w)
9
3
Recent ratings
25
15
BDX

Becton Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.

NPCE

Neuropace Inc.

NeuroPace, Inc. operates as a medical device company in the United States. The company develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. Its RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

Latest BDX

Latest NPCE